Transmission-Blocking Vaccines: Focus on Anti-Vector Vaccines against Tick-Borne Diseases

Tick-borne diseases are a potential threat that account for significant morbidity and mortality in human population worldwide. Vaccines are not available to treat several of the tick-borne diseases. With the emergence and resurgence of several tick-borne diseases, emphasis on the development of transmission-blocking vaccines remains increasing. In this review, we provide a snap shot on some of the potential candidates for the development of anti-vector vaccines (a form of transmission-blocking vaccines) against wide range of hard and soft ticks that include Ixodes, Haemaphysalis, Dermacentor, Amblyomma, Rhipicephalus and Ornithodoros species

A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase

Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year 685 million people. In about one third of cases, this virus affects children under five years of age, causing each year up to 200,000 child deaths, mainly in the developing countries. Norovirus outbreaks are associated with very significant economic losses, with an estimated societal cost of 60 billion dollars per year. Despite the marked socio-economic consequences associated, no therapeutic options or vaccines are currently available to treat or prevent this infection. One promising target to identify new antiviral agents for norovirus is the viral polymerase, which has a pivotal role for the viral replication and lacks closely homologous structures in the host. Starting from the scaffold of a novel class of norovirus polymerase inhibitors recently discovered in our research group with a computer-aided method, different new chemical modifications were designed and carried out, with the aim to identify improved agents effective against norovirus replication in cell-based assays. While different new inhibitors of the viral polymerase were found, a further computer-aided ligand optimisation approach led to the identification of a new antiviral scaffold for norovirus, which inhibits human norovirus replication at low-micromolar concentrations.status: Published onlin

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Multinationality and performance literature: a critical review and future research agenda

The literature on the relationship between the degree of multinationality (M) and performance (P) in the context of multinational enterprises (MNEs) has attracted a large volume of research in the past 50 years. Yet, the theoretical foundations and the empirical conclusions concerning the nature of M–P relationship vary greatly, thus call for a critical review and assessment. We examine 135 articles in 39 leading scholarly journals and classic books published during the period 1960–2015. We use an inductive approach and a qualitative content analysis methodology for our comprehensive and critical review of the literature. We incorporate international business, finance, and accounting perspectives in our analysis. We review the conceptualization and measurement of M, P, the findings on M–P relationships, methodologies, and geographic focus. We identify six key inconsistencies in the existing research, which cause ambiguity in the relevant findings. We make eight recommendations for future research to address these inconsistencies. Thus, our study contributes to the central debate in this research field

Not Available

Not AvailableNot AvailableNot Availabl

Not Available

Not AvailableRabbit haemorrhagic disease (RHD), also known as viral haemorrhagic disease was a highly infectious and contagious disease affecting only European rabbits. It is caused by a host-specific calicivirus, called RHD virus (RHDV). The virus once used to control rabbit population in Australia is currently an important transboundary pathogen causing economic losses to the rabbit industry. RHDV appears to have evolved from a pre-existing avirulent rabbit calicivirus circulating in Europe, Australia and New Zealand. However, there is no conclusive proof. Emergence of RHDV was first detected in 1984 in China and then spread to Asia, Europe, Africa, Americas, Australia and New Zealand. With the evolution process, either by mutation or recombination or otherwise, there was antigenic drift in the original RHDV population (of 1984) leading to the development of antigenic variant RHDV2 (different serotype) that was detected in 2010, and is currently in circulation causing RHD with broader host susceptibility, and has almost replaced the parent serotype (RHDV1) of 1984. The death rate is observed to be 40-100% for RHDV1 and 5-70% for RHDV2. Rabbits vaccinated with RHDV1 are not protected from RHDV2 infection. The current review includes virology, pathology, epidemiology, diagnosis and prevention of RHD.Not Availabl

Not Available

Not AvailableTime space between waves of Covid-19 is linked to selection of most appropriate virus mutant(s)/variant(s), in the Spike (S) gene, generated during massive and error prone replication of the virus in the human populations that are either naive or partially immune due to infection immunity or vaccinal immunity, having higher transmissibility with immune-escape feature and increased pathogenicity. The mutations in the S gene have been found to be progressive to resist prevalent virus neutralizing antibodies in the hosts. The first mutation of significance was D (Asp) to G (Gly) at the position 614 of the Spike protein, over the original Wuhan strain/virus. Subsequently, with in a short time span of less than 18 months since December 2019, many Variants/mutants of SARS-CoV-2, viz., B.1.1.7, B.1.427, B.1.1.28.2, B.1.429, B.1.617, B.1.351, and P.1 have been found associated with the current waves of the Covid-19 pandemic in different countries. The latest significant S variants identified in the second wave in India and elsewhere are B.1.617 and its Kappa (k), Delta (8) and Delta plus (8+; Lys to Asn at position 417) strains, in the order of appearance. The lambda (X) variant is prevalent in South America. The P.2 variant B.1.1.28.2 was antigenically dominant over B.1 D614G virus. The k and 8 variants of the S gene were partially resistant to neutralization by existing vaccinal antibodies, and the 8 variant has been feared to ignite third wave in many countries of Americas, Asia and Europe. The SARS-CoV-2 possibly has ‘Quasispecies’ structure, like the transboundary animal pathogen Foot and Mouth Disease (FMD) virus, and continuous forward mutations in the S gene has been the cause of the fact that "previous immunity acquired during the course of the natural infection (or vaccination) is not fully competent to protect against subsequent mutants selected (in the nature) that leads to new waves of the disease". The waves of Covid-19 have been guided by emergence of sequential antigenic variants, e.g. B.1 D614G virus ^B.1 8 mutant ^B.1 8+ mutant. Intermittent/inter-wave drop in incidence of the infection between the Covid-19 waves could be attributed to very short term (less than 3 months?) infection/vaccination immunity that is breached by the successive antigenic mutant (s) selected. Vaccination and virus circulation happening simultaneously, can facilitate faster selection of neutralization-escape mutants, which is now evident and may lead to new waves of the disease/infection at short intervals of less than 6 months. All variants described here are antigenically dissimilar, whereas the current Covid-19 vaccines are monovalent. Therefore, it may be essential and beneficial to have multivalent vaccines or with higher antigenic mass in monovalent vaccines. Further, it is required that nasal swabs of a certain percentage of vaccinates be collected at the time of vaccination and preserved for retrospect analysis of their infection status, that in turn will reveal the infection status of the population in villages/cities/districts/State.Not Availabl

Not Available

Not AvailableNot AvailableNot Availabl

Botryomycosis

Botryomycosis is a rare chronic bacterial granulomatous disease that usually involves skin and rarely viscera. Main etiological agent is Staphylococcus aureus and less commonly Pseudomonas spp., Escherichia coli, Proteus spp., Streptococcus spp. We here report a case of 32-year-old male with polymicrobial botryomycosis on forehead and on frontal scalp. Culture from lesions revealed growth of S. aureus initially. Partial resolution was achieved with cefadroxyl and clavulanic acid, rifampicin, and linezolid. Subsequent repeat culture revealed E. coli sensitive to netilmycin. Slow and steady resolution was achieved with surgical debridement and combination therapy of injectable netilmycin and oral sufomethoxazole and trimethoprim for a prolonged period